The context and potential of epigenetics in oncology
Open Access
- 17 February 2009
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (4) , 571-577
- https://doi.org/10.1038/sj.bjc.6604930
Abstract
Cancer has long been known to be a disease caused by alterations in the genetic blueprint of cells. In the past decade it has become evident that epigenetic processes have a function, at least equally important, in neoplasia. Epigenetics describes the mechanisms that result in heritable alterations in gene expression profiles without an accompanying change in DNA sequence. Genetics and epigenetics intricately interact in the pathogenesis of cancer ( Esteller, 2007). In this review, we paint a broad picture of current understanding of epigenetic changes in cancer cells and reflect on the immense clinical potential of emerging knowledge of epigenetics in the diagnosis, prognostic assessment, treatment, and screening of cancer.Keywords
This publication has 61 references indexed in Scilit:
- Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle StudyPLOS ONE, 2008
- A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysisNature Biotechnology, 2008
- Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control studyThe Lancet Oncology, 2008
- Sequential gene promoter methylation during HPV-induced cervical carcinogenesisBritish Journal of Cancer, 2007
- The Epigenomics of CancerPublished by Elsevier ,2007
- A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencingNature Genetics, 2007
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinomaGenes, Chromosomes and Cancer, 2002
- Aberrant CpG-island methylation has non-random and tumour-type–specific patternsNature Genetics, 2000
- A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancerOncogene, 1999